Question 1

What is RP902?

Accepted Answer

RP902 is a Other.

Question 2

How often does RP902 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was RP902 first tracked by Ergen?

Accepted Answer

First tracked on May 19, 2026.

Question 4

When was RP902 last mentioned in news?

Accepted Answer

Last active on May 22, 2026.

Question 5

What is RP902's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is RP902 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving RP902?

Accepted Answer

Risen Pharma initiates RP902 Phase 2 (May 19, 2026, 7 articles).

Question 8

How did the "Risen Pharma initiates RP902 Phase 2" event impact RP902?

Accepted Answer

RP902 is the oral small-molecule drug undergoing a Phase 2 clinical trial for mild cognitive impairment due to Alzheimer s disease, representing a key asset for Risen Pharma.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.